Changes to This Summary (05/11/2012)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Stage IV and Recurrent Melanoma ¹

Added text ² to state that treatment with vemurafenib is discouraged in wild-type BRAF melanoma because data from preclinical models has demonstrated that BRAF inhibitors can enhance rather than downregulate the MAPK (mitogen-activated protein kinase) pathway in tumor cells with wild-type BRAF and upstream RAS mutations (cited Heidorn et al., Hatzivassiliou et al., Poulikakos et al., and Su et al. as references 24, 25, 26, and 27, respectively).

Added text ³ to include levels of evidence 1iiA and 1iiDiii.

Added text ⁴ about the results of a multicenter phase II trial of vemurafenib in which 132 patients with a BRAF V600E or BRAF V600K mutation were enrolled (cited Sosman et al. as reference 28 and level of evidence 3iiiDiv).